EUVIMEDObjevte EUVIMED
Crossref

Design, synthesis and characterization of ethyl 3‐benzoyl‐7‐morpholinoindolizine ‐1‐carboxylate as anti‐tubercular agents: In silico screening for possible target identification

Priya Tiwari iD, Gayakvad Sunitaben Mangubhai iD, Saqib Kidwai iD, Ramandeep Singh iD, Sandeep Chandrashekharappa iD

Chemical Biology & Drug Design · 2024

DOI: 10.1111/cbdd.14512 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2024. Written by Priya Tiwari and 4 co-authors. Institution: Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Raebareli, Lucknow, India. Major MEDLINE topics: Mycobacterium tuberculosis, Tuberculosis. Cited 12 times so far (Crossref); 45 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

A thorough search for the development of innovative drugs to treat tuberculosis, especially considering the urgent need to address developing drug resistance, we report here a synthetic series of ethyl 3‐benzoyl‐7‐morpholinoindolizine‐1‐carboxylate analogues ( 5a‐o ) as potent anti‐tubercular agents. These morpholino‐indolizines were synthesized by reacting 4‐morpholino pyridinium salts, with various electron‐deficient acetylenes to afford the ethyl 3‐benzoyl‐7‐morpholinoindolizine‐1‐carboxylate analogues ( 5a‐o ). All synthesized intermediate and final compounds are characterized by spectroscopic methods such as 1 H NMR, 13 C NMR and HRMS and further examined for their anti‐tubercular activity against the M. tuberculosis H37Rv strain (ATCC 27294—American type cell culture). All the compounds screened for anti‐tubercular activity in the range of 6.25–50 μM against the H37Rv strain of Mycobacterium tuberculosis . Compound 5g showed prominent activity with MIC 99 2.55 μg/mL whereas compounds 5d and 5j showed activity with MIC 99 18.91 μg/mL and 25.07 μg/mL, respectively. In silico analysis of these compounds revealed drug‐likeness. Additionally, the molecular target identification for Malate synthase (PDB 5CBB) is attained by computational approach. The compound 5g with a MIC 99 value of 2.55 μg/mL against M. tuberculosis H37Rv emerged as the most promising anti‐TB drug and in silico investigations suggest Malate synthase (5CBB) might be the compound's possible target.

Subjects

MeSH terms (MEDLINE)

Mycobacterium tuberculosisTuberculosisHumansAntitubercular AgentsStructure-Activity RelationshipMalate SynthaseMorpholinosMolecular Docking SimulationMicrobial Sensitivity Tests

Author keywords

M. tuberculosisTuberculosisin silicoH37Rvcharacterizationin vitro studiesmolecular dockingmolecular simulationmorpholino‐Indolizinessynthesis

Substances

Antitubercular AgentsMalate SynthaseMorpholinos

Authors and institutions

  • Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Raebareli, Lucknow, India.
  • Tuberculosis Research Laboratory, Translational Health Science and Technology Institute, Faridabad, India.

ORCID profiles: Priya Tiwari, Gayakvad Sunitaben Mangubhai, Saqib Kidwai, Ramandeep Singh, Sandeep Chandrashekharappa

Cite

APA

Tiwari, P., Mangubhai, G. S., Kidwai, S., Singh, R., & Chandrashekharappa, S. (2024). Design, synthesis and characterization of ethyl 3‐benzoyl‐7‐morpholinoindolizine ‐1‐carboxylate as anti‐tubercular agents: In silico screening for possible target identification. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14512

Vancouver

Tiwari P, Mangubhai GS, Kidwai S, Singh R, Chandrashekharappa S. Design, synthesis and characterization of ethyl 3‐benzoyl‐7‐morpholinoindolizine ‐1‐carboxylate as anti‐tubercular agents: In silico screening for possible target identification. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14512

BibTeX
@article{Tiwari2024,
  author = {Tiwari, Priya and Mangubhai, Gayakvad Sunitaben and Kidwai, Saqib and Singh, Ramandeep and Chandrashekharappa, Sandeep},
  title = {Design, synthesis and characterization of ethyl 3‐benzoyl‐7‐morpholinoindolizine ‐1‐carboxylate as anti‐tubercular agents: In silico screening for possible target identification},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  doi = {10.1111/cbdd.14512}
}
Start for free →